Neuromethods,
Journal Year:
2023,
Volume and Issue:
unknown, P. 3 - 47
Published: Jan. 1, 2023
Alzheimer's
disease
(AD)
is
a
neurological
ailment
that
affects
older
people
and
causes
steady
decline
in
their
cognitive
function.
The
impairments
found
are
presumed
to
be
the
result
of
synapse
disruption
neurochemical
deficits.
Several
abnormalities
have
been
throughout
progressive
aging,
these
connected
dysfunction
seen
sporadic
stage
AD.
There
various
hypotheses
explaining
AD,
such
as
aberrant
deposits
amyloid
β
(Aβ)
protein
extracellular
spaces
neurons,
production
twisted
fibers
tau
proteins
inside
cholinergic
neuron
damage,
inflammation,
oxidative
stress,
so
on,
many
anti-AD
therapeutics
developed
based
on
hypotheses.
While
current
pharmacological
treatments
assist
relieving
symptoms
AD
enhance
patient's
quality
life,
they
do
not
halt
or
cure
disease.
Presently,
targeted
drug
delivery
central
nervous
system
(CNS)
for
therapy
hampered
by
difficulties
posed
blood-brain
interfaces
surrounding
CNS,
reducing
therapeutic
bioavailability.
Among
innovative
ways
overcome
restrictions
successfully
deliver
pharmaceuticals
nanoparticles
(NPs)
can
barriers,
offering
new
strategies
terms
dealing
drugs
cross
barrier
(BBB)
enter
brain
more
adequately.
Various
options
treatment
shown
promising
results
preclinical
research
currently
being
tested
clinical
trials
last
decade.
In
addition
generating
chemical
entities,
natural
compounds
alkaloids,
terpenoids,
flavonoids,
curcumin
isolated
evaluated
all
demonstrated
actions
against
range
targets.
Moreover,
computational
techniques
also
proven
quite
useful
time
money
when
developing
therapies.
Molecular
modeling,
virtual
screening,
docking
widely
used
researchers
worldwide
recent
years.
These
already
aided
development
several
compounds.
purpose
this
chapter
summarize
highlight
advancements
novel
therapies
implications
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(15), P. 8493 - 8493
Published: July 31, 2022
Depression
is
a
common
and
serious
disorder,
characterized
by
symptoms
like
anhedonia,
lack
of
energy,
sad
mood,
low
appetite,
sleep
disturbances.
This
disease
very
complex
not
totally
elucidated,
in
which
diverse
molecular
biological
mechanisms
are
involved,
such
as
neuroinflammation.
There
high
need
for
the
development
new
therapies
gaining
insights
into
this
urgent.
One
important
player
depression
amino
acid
tryptophan.
can
be
metabolized
two
pathways
context
depression:
serotonin
kynurenine
pathways.
These
metabolic
tryptophan
crucial
several
processes
that
linked
with
depression.
Indeed,
maintenance
balance
critical
human
physiological
homeostasis.
Thus,
narrative
review
aims
to
explore
metabolism
(particularly
pathways)
depression,
starting
global
overview
about
these
topics
ending
focus
on
neuroinflammation,
stress,
microbiota,
brain-derived
neurotrophic
factor
regulation
disease.
Taken
together,
information
clarify
particularly
Antioxidants,
Journal Year:
2023,
Volume and Issue:
12(2), P. 470 - 470
Published: Feb. 13, 2023
Depression
is
a
prevalent,
complex,
and
highly
debilitating
disease.
The
full
comprehension
of
this
disease
still
global
challenge.
Indeed,
relapse,
recurrency,
therapeutic
resistance
are
serious
challenges
in
the
fight
against
depression.
Nevertheless,
abnormal
functioning
stress
response,
inflammatory
processes,
neurotransmission,
neurogenesis,
synaptic
plasticity
known
to
underlie
pathophysiology
mental
disorder.
role
oxidative
and,
particularly,
depression
widely
recognized,
being
important
for
both
its
onset
development.
excessive
generation
reactive
oxygen
species
lack
efficient
antioxidant
response
trigger
processes
such
as
inflammation,
neurodegeneration,
neuronal
death.
Keeping
mind
importance
detailed
study
about
cellular
molecular
mechanisms
that
present
depression,
review
focuses
on
link
between
neuroinflammation,
serotonergic
pathways,
plasticity's
imbalances
these
lead
new
era
treatment
knowledge
complex
Biomolecules,
Journal Year:
2025,
Volume and Issue:
15(1), P. 110 - 110
Published: Jan. 12, 2025
Aromatic
plants
are
rich
sources
of
essential
oils
(EOs),
recognized
for
their
therapeutic
properties
due
to
diversity
phytochemicals.
This
study
investigated
the
anxiolytic
and
antidepressant
effects
Myrcia
sylvatica
oil
(MsEO)
through
inhalation
in
an
animal
model
its
vitro
anticholinesterase
(AChE)
activity.
The
EO
was
obtained
by
hydrodistillation,
volatile
constituents
were
analyzed
GC-MS.
Swiss
mice
exposed
doses
0.1%,
1%,
2%
via
apparatus.
activity
assessed
using
elevated
plus
maze
light-dark
box
tests,
while
evaluated
tail
suspension
forced
swimming
tests.
To
examine
potential
side
effects,
animals
subjected
rotarod,
Y-maze,
Morris
water
tests
assess
motor
coordination,
memory,
learning.
Anticholinesterase
determined
direct
bioautography
colorimetry
based
on
Ellman
method.
results
demonstrated
that
MsEO
at
0.1%
1%
significantly
reduced
anxiety
depressive-like
behaviors
without
impairing
learning,
or
coordination
animals.
Moreover,
inhibited
acetylcholinesterase
with
IC50
0.47
μg/mL.
These
findings
suggest
has
applications
depression
disorders,
additional
warranting
further
investigation
cognitive-related
conditions.
ACS Chemical Neuroscience,
Journal Year:
2024,
Volume and Issue:
15(21), P. 3800 - 3827
Published: Oct. 11, 2024
Alzheimer's
disease
(AD)
is
a
progressive
neurodegenerative
disorder
characterized
by
cognitive
decline,
memory
loss,
and
impaired
daily
functioning.
The
pathology
of
AD
marked
the
accumulation
amyloid
beta
plaques
tau
protein
tangles
in
brain,
along
with
neuroinflammation
synaptic
dysfunction.
Genetic
factors,
such
as
mutations
APP,
PSEN1,
PSEN2
genes,
well
APOE
ε4
allele,
contribute
to
increased
risk
acquiring
AD.
Currently
available
treatments
provide
symptomatic
relief
but
do
not
halt
progression.
Research
efforts
are
focused
on
developing
disease-modifying
therapies
that
target
underlying
pathological
mechanisms
Advances
identification
validation
reliable
biomarkers
for
hold
great
promise
enhancing
early
diagnosis,
monitoring
progression,
assessing
treatment
response
clinical
practice
effort
alleviate
burden
this
devastating
disease.
In
paper,
we
analyze
data
from
CAS
Content
Collection
summarize
research
progress
We
examine
publication
landscape
insights
into
current
knowledge
advances
developments.
also
review
most
discussed
emerging
concepts
assess
strategies
combat
explore
genetic
pharmacological
targets,
comorbid
diseases.
Finally,
inspect
applications
products
against
their
development
pipelines
drug
repurposing.
objective
broad
overview
evolving
regarding
AD,
outline
challenges,
evaluate
growth
opportunities
further
combating
Frontiers in Pharmacology,
Journal Year:
2021,
Volume and Issue:
12
Published: Dec. 24, 2021
Depression
is
a
risk
factor
for
the
development
of
Alzheimer's
disease
(AD).
A
neurobiological
and
clinical
continuum
exists
between
AD
depression,
with
neuroinflammation
oxidative
stress
being
involved
in
both
diseases.
Second-generation
antidepressants,
particular
selective
serotonin
reuptake
inhibitors
(SSRIs),
are
currently
investigated
as
neuroprotective
drugs
AD.
By
employing
non-transgenic
model,
obtained
by
intracerebroventricular
(i.c.v.)
injection
amyloid-β
(Aβ)
oligomers
2-month-old
C57BL/6
mice,
we
recently
demonstrated
that
SSRI
fluoxetine
(FLX)
multimodal
antidepressant
vortioxetine
(VTX)
reversed
depressive-like
phenotype
memory
deficits
induced
Aβ
rescuing
levels
transforming
growth
factor-β1
(TGF-β1).
Aim
our
study
was
to
test
FLX
VTX
their
ability
prevent
hippocampus
Aβ-injected
brain
area
strongly
affected
depression
The
long-term
intraperitoneal
(i.p.)
administration
(10
mg/kg)
or
(5
10
24
days,
starting
7
days
before
injection,
able
over-expression
inducible
nitric
oxide
synthase
(iNOS)
NADPH
oxidase
2
(Nox2)
oligomers.
Antidepressant
pre-treatment
also
rescue
mRNA
expression
glutathione
peroxidase
1
(Gpx1)
antioxidant
enzyme.
prevented
Aβ-induced
neurodegeneration
mixed
neuronal
cultures
treated
Our
data
represent
first
evidence
treatment
antidepressants
can
phenomena
related
cognitive
observed
animal
model
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(13), P. 10808 - 10808
Published: June 28, 2023
Increased
monoamine
oxidase-A
(MAO-A)
activity
in
Alzheimer’s
disease
(AD)
may
be
detrimental
to
the
point
of
neurodegeneration.
To
assess
MAO-A
AD,
we
compared
four
biomarkers,
Aβ
plaques,
tau,
translocator
protein
(TSPO),
and
postmortem
AD.
Radiotracers
were
[18F]FAZIN3
for
MAO-A,
[18F]flotaza
[125I]IBETA
[124/125I]IPPI
[18F]FEPPA
TSPO
imaging.
Brain
sections
anterior
cingulate
(AC;
gray
matter
GM)
corpus
callosum
(CC;
white
WM)
from
cognitively
normal
control
(CN,
n
=
6)
AD
(n
subjects
imaged
using
autoradiography
immunostaining.
Using
competition
with
clorgyline
(R)-deprenyl,
binding
was
confirmed
selective
levels
brain
sections.
Increases
plaque,
found
brains
brains.
The
ratio
GM
versus
CN
2.80,
suggesting
a
180%
increase
activity.
GM-to-WM
ratios
CN,
>50%
observed
(AD/CN
1.58).
Linear
positive
correlations
[18F]flotaza,
[125I]IBETA,
[125I]IPPI
measured
suggested
an
increases
plaques
tau
Our
results
support
finding
that
is
elevated
cortex
thus
provide
new
biomarker
this
region.
Frontiers in Medicine,
Journal Year:
2024,
Volume and Issue:
11
Published: Dec. 16, 2024
Alzheimer's
disease
(AD)
is
a
chronic,
progressive
neurodegenerative
disorder
characterized
by
cognitive
decline,
memory
loss,
and
impaired
reasoning.
It
the
leading
cause
of
dementia
in
older
adults,
marked
pathological
accumulation
amyloid-beta
plaques
neurofibrillary
tangles.
These
changes
lead
to
widespread
neuronal
damage,
significantly
impacting
daily
functioning
quality
life.
Angewandte Chemie International Edition,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 22, 2025
Photodynamic
therapy
(PDT)
has
emerged
as
a
promising
targeted
treatment
for
cancer.
However,
current
PDT
is
limited
by
low
tissue
penetration,
insufficient
phototoxicity
(toxicity
with
light
irradiation),
and
undesirable
cytotoxicity
without
irradiation).
Here,
we
report
the
discovery
of
cyanine-carborane
salts
potent
photosensitizers
(PSs)
that
harness
near-infrared
(NIR)
absorbing
[cyanine+]
inertness
[carborane-].
The
implementation
[carborane-]
dramatically
enhance
cancer
targeting
PSs
decrease
cytotoxicity.
We
characterize
cellular
uptake
PSs,
organelle
localization,
generation
reactive
oxygen
species
(ROS)
ability
to
cogenerate
multiple
ROS
species,
suppression
pro-metastatic
pathways,
activation
apoptotic
pathways.
further
demonstrate
optimized
eliminate
tumors
in
vivo
using
an
orthotopic
mouse
model
breast
These
newly
developed
salt
introduce
therapeutic
approach
against
aggressive
while
decreasing
side
effects.
Angewandte Chemie,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 22, 2025
Abstract
Photodynamic
therapy
(PDT)
has
emerged
as
a
promising
targeted
treatment
for
cancer.
However,
current
PDT
is
limited
by
low
tissue
penetration,
insufficient
phototoxicity
(toxicity
with
light
irradiation),
and
undesirable
cytotoxicity
without
irradiation).
Here,
we
report
the
discovery
of
cyanine‐carborane
salts
potent
photosensitizers
(PSs)
that
harness
near‐infrared
(NIR)
absorbing
[cyanine
+
]
inertness
[carborane
−
].
The
implementation
dramatically
enhance
cancer
targeting
PSs
decrease
cytotoxicity.
We
characterize
cellular
uptake
PSs,
organelle
localization,
generation
reactive
oxygen
species
(ROS)
ability
to
cogenerate
multiple
ROS
species,
suppression
pro‐metastatic
pathways,
activation
apoptotic
pathways.
further
demonstrate
optimized
eliminate
tumors
in
vivo
using
an
orthotopic
mouse
model
breast
These
newly
developed
salt
introduce
therapeutic
approach
against
aggressive
while
decreasing
side
effects.